+400.7%
FSLR vs MRNA
+537.9%
-137.2%
-60.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.3% | -3.6% | +7.9% | +4.5% |
| 7D | +6.8% | -9.0% | +15.8% | +7.4% |
| 30D | -14.7% | +137.2% | -151.9% | -22.8% |
| 3M | -22.6% | +194.8% | -217.4% | -31.8% |
| 6M | +12.7% | +167.2% | -154.5% | 0.0% |
| YTD | -18.4% | +375.9% | -394.2% | -32.0% |
| 1Y | +4.9% | +465.2% | -460.2% | -14.3% |
| 3Y | +16.4% | +30.4% | -14.0% | +6.0% |
| 5Y | +123.5% | -66.8% | +190.3% | +109.2% |
| All | +400.7% | +537.9% | -137.2% | +368.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling